Data Requirements for Patenting Biotech/Pharma Inventions in China and the EU

In Webinars

1 July, 2020

This interactive webinar considers the filing and post-filing data requirements for biotechnology and pharmaceutical-related inventions in China and the EU. Xiaofan Chen, Hai Liu and Helle Friis Svenstrup from AWA’s Asian and European offices explain the minimum data requirements during filing and also the criteria for supplementary data. They also consider the use of post-grant data as evidence during invalidation proceedings. Understanding the differences between the European and Chinese regimes is essential for applicants to be successful.

 

 

 

You may also be interested in:

China endorses good-faith commitment when applying for well-known status

From 1 September 2021 applicants and their trademark agents or representing agency will be required to sign and seal

Read more...

The Business of IP – Understanding and Creating Value: Part 5 – Negotiations

In this six-part series, Anders Isaksson explores some of the critical factors and motivators for why companies, small or

Read more...

Determining the Value of Patents during an Investment or Sale

Joanna Applequist and Mikael Henriksson speak on IP matters that companies should consider preparing for during an investment or sale during this seminar

Read more...

Mobile Sliding Menu